| P50 | author | Stephen P Methot | Q59599651 |
| P2093 | author name string | Andrew I Minchinton | |
| | Jennifer H E Baker | |
| | Alastair H Kyle | |
| | Andrew Balbirnie | |
| | Erin J Flanagan | |
| | Jordan D Cran | |
| | Kirsten L Bartels | |
| P2860 | cites work | Tirapazamine: a hypoxia-activated topoisomerase II poison. | Q40703792 |
| | Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity | Q41099312 |
| | Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors | Q41213138 |
| | HMEC-1: establishment of an immortalized human microvascular endothelial cell line | Q41592068 |
| | Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial | Q42655101 |
| | Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia | Q43201834 |
| | Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. | Q43614988 |
| | Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy | Q44240071 |
| | Detecting vascular-targeting effects of the hypoxic cytotoxin tirapazamine in tumor xenografts using magnetic resonance imaging. | Q45990406 |
| | Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation | Q46581099 |
| | Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia. | Q46585364 |
| | Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. | Q46863012 |
| | Exploring vascular dysfunction caused by tirapazamine | Q46892913 |
| | Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts | Q46925103 |
| | Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine | Q48794511 |
| | Nitric oxide synthases catalyze the activation of redox cycling and bioreductive anticancer agents. | Q52034388 |
| | Cryospectrophotometric determination of tumor intravascular oxyhemoglobin saturations: dependence on vascular geometry and tumor growth | Q67972205 |
| | Molecular mechanisms involved in superoxide-induced leukocyte-endothelial cell interactions in vivo | Q72672866 |
| | Induction of hypoxia in experimental murine tumors by the nitric oxide synthase inhibitor, NG-nitro-L-arginine | Q72875256 |
| | Intratumour heterogeneity in microvessel oxyhaemoglobin saturations | Q73366750 |
| | Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study | Q79699625 |
| | Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts | Q80996595 |
| | Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group | Q28282755 |
| | Hypoxia in cancer: significance and impact on clinical outcome | Q28298305 |
| | SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells | Q28303921 |
| | Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide | Q29547245 |
| | Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. | Q30990659 |
| | Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine | Q31983068 |
| | AQ4N: a new approach to hypoxia-activated cancer chemotherapy | Q34097489 |
| | The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents | Q34122191 |
| | Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation | Q34276958 |
| | Mechanisms underlying hypoxia development in tumors. | Q35064150 |
| | Vascular targeting agents as cancer therapeutics | Q35647684 |
| | Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome | Q35668680 |
| | Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions | Q35764739 |
| | Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer | Q35836427 |
| | Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing | Q35994700 |
| | Cellular abnormalities of blood vessels as targets in cancer | Q36015542 |
| | Disrupting tumour blood vessels | Q36146900 |
| | Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours. | Q36291917 |
| | Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase | Q36430899 |
| | The role of nitric oxide in tumour progression | Q36516414 |
| | Tirapazamine: from bench to clinical trials. | Q37230218 |
| | Tumour vascular disrupting agents: combating treatment resistance | Q37280244 |
| | Brain metastases as preventive and therapeutic targets | Q37862581 |
| | The histological structure of some human lung cancers and the possible implications for radiotherapy | Q39979244 |
| | Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. | Q39996248 |
| | Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors | Q40138487 |
| | Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. | Q40595394 |
| | Redox signaling: nitrosylation and related target interactions of nitric oxide | Q40630842 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | hypoxia | Q105688 |
| P304 | page(s) | e76832 | |
| P577 | publication date | 2013-10-28 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Targeting the tumour vasculature: exploitation of low oxygenation and sensitivity to NOS inhibition by treatment with a hypoxic cytotoxin | |
| P478 | volume | 8 | |